Table 2.
Rate of a cure depending on the first-line treatment and surgery in the whole cohort.
| Rate of Cure | ||||||
|---|---|---|---|---|---|---|
| Group | First-Line Treatment | p * | Surgery | p * | ||
| TSS, n (%) | DA, n (%) | yes | no | |||
| Whole Cohort | 56/119 (47.1) | 57/140 (40.7) | 0.3172 | 97/194 (50.0) | 16/65 (24.6) | 0.0005 |
| Female | 38/56 (67.9) | 49/108 (45.4) | 0.0081 | 72/113 (63.7) | 15/51 (29.4) | <0.0001 |
| Male | 18/63 (28.6) | 8/32 (25) | 0.8102 | 25/81 (30.9) | 1/14 (7.1) | 0.1026 |
| Microadenomas | 25/41 (61.0) | 41/84 (48.8) | 0.2530 | 52/78 (78.8) | 14/47 (21.2) | <0.0001 |
| Macroadenomas | 31/78 (39.7) | 16/56 (28.6) | 0.2028 | 45/116 (38.8) | 2/18 (11.1) | 0.0031 |
| Female: microadenomas | 20/29 (69.0) | 37/76 (48.7) | 0.0080 | 44/62 (71.0) | 13/43 (30.2) | <0.0001 |
| Female: macroadenomas | 18/27 (66.7) | 12/32 (37.5) | 0.0370 | 28/51 (54.9) | 2/8 (25) | 0.1455 |
| Male: microadenomas | 5/12 (41.7) | 4/8 (50) | >0.9999 | 8/16 (50) | 1/4 (25) | 0.5913 |
| Male: macroadenomas | 13/51 (25.5) | 4/24 (16.7) | 0.5566 | 17/65 (26.2) | 0/10 (0) | 0.1043 |
DA, dopamine-agonist; TSS, trans-sphenoidal surgery; *, Fisher’s exact test; n, number of patients.